Biotech Stock Roundup: Alnylam Slumps On Revusiran Update, TESARO Impresses At ESMO
October 12, 2016 at 12:14 PM EDT
Alnylam focused on developing novel therapeutics based on RNA interference (RNAi), saw its shares slump on its decision to discontinue the development of a late-stage pipeline candidate.